study were obtained from the PHARMO Record Linkage System, including among others linked drug-dispensing and hospital records of approximately three million individuals in defined areas of The Netherlands. Users of TC during 1992TC during -2004, without diabetes, with Ն4 years of follow-up were selected. Diabetes onset was defined as first occurrence (index date) of an antidiabetic drug dispensing or hospitalization for diabetes or diabetes-related diagnoses. Each case was matched by age and sex to 4 controls without diabetes, with similar follow-up duration. Use of TC and systemic corticosteroids (SC) and/or inhaled corticosteroids (IC) as co medication were classified as current (Յ2 years before index date), recent (4-2 years ago) and past/never (>4 years ago). Multivariate regression adjusted for co-medication and co-morbidity. RESULTS: Among 192,893 incident TC users, 2,212 developed diabetes and could be matched to 8,582 controls. Current TC use was associated with a 1.24 times increased risk of diabetes (95% CI 1.11-1.40). The Odds Ratio increased to 1.32 with >180 days of TC use and to 1.44 with a cumulative TC load (combined potency and units) 731-1,460 mg. Cases more often used SC and IC than controls (23% versus 17% and 18% versus 13% respectively). Among "Past/never" users of SC and/or IC, risk of diabetes with current TC use was 1.25 (95% CI 1.09-1.43); among "Current" users of SC and/or IC, this OR was 1.13 (95%CI 0.88 1.44). CONCLU-SION: A statistically significant effect of TC use on diabetes was found. Use of TC as skin treatment among patients at increased risk of diabetes should be considered with some caution. 2 GlaxoSmithKline Spa, Verona, Veneto, Italy OBJECTIVES: To implement a flexible PC program to support decision makers in evaluating the impact of the use of rosiglitazone in eligible diabetic patients on the Italian National Health System budget. METHODS: Rosiglitazone, an insulin-sensitising drug, is indicated for subjects with inadequate glycaemic control both as monotherapy, in those contraindicated to metformin (especially if overweight) and as combination therapy with metformin, sulphonylureas or both. The software developed has a user-friendly interface and is based on an analytic model, which pathway may be summarized as follows: a) estimate of the number of Italian type 2 diabetes patients, grouped according to current therapeutic classes; b) estimate of the number of patients with inadequate glycaemic control for each subgroup; c) identification of patients eligible to rosiglitazone treatment; d) identification of the comparator strategy for each patient sub-group; e) comparison of costs for each couple of alternative options; and f) calculation of budget impact. The user can modify most default data to adapt the analysis to the specific setting. RESULTS: Default data based scenario shows that adoption of rosiglitazone monotherapy induces a mild cost increase. Combination treatments induce significant cost savings, related to lower resource consumption for glycaemic auto-monitoring and hypoglycaemia management, as compared to standard combination therapies. The hypothetical scenario in which all eligible Italian patients are treated with rosiglitazone is estimated to induce net savings for about 260 millions Euro per year. CONCLUSION: In type 2 diabetes, the maintenance of non-diabetic glycaemic levels has been shown to decrease the onset of long term complications.
The Odds Ratio increased to 1.32 with >180 days of TC use and to 1.44 with a cumulative TC load (combined potency and units) 731-1,460 mg. Cases more often used SC and IC than controls (23% versus 17% and 18% versus 13% respectively). Among "Past/never" users of SC and/or IC, risk of diabetes with current TC use was 1.25 (95% CI 1.09-1.43); among "Current" users of SC and/or IC, this OR was 1.13 (95%CI 0.88 1.44). CONCLU-SION: A statistically significant effect of TC use on diabetes was found. Use of TC as skin treatment among patients at increased risk of diabetes should be considered with some caution. To implement a flexible PC program to support decision makers in evaluating the impact of the use of rosiglitazone in eligible diabetic patients on the Italian National Health System budget. METHODS: Rosiglitazone, an insulin-sensitising drug, is indicated for subjects with inadequate glycaemic control both as monotherapy, in those contraindicated to metformin (especially if overweight) and as combination therapy with metformin, sulphonylureas or both. The software developed has a user-friendly interface and is based on an analytic model, which pathway may be summarized as follows: a) estimate of the number of Italian type 2 diabetes patients, grouped according to current therapeutic classes; b) estimate of the number of patients with inadequate glycaemic control for each subgroup; c) identification of patients eligible to rosiglitazone treatment; d) identification of the comparator strategy for each patient sub-group; e) comparison of costs for each couple of alternative options; and f) calculation of budget impact. The user can modify most default data to adapt the analysis to the specific setting. RESULTS: Default data based scenario shows that adoption of rosiglitazone monotherapy induces a mild cost increase. Combination treatments induce significant cost savings, related to lower resource consumption for glycaemic auto-monitoring and hypoglycaemia management, as compared to standard combination therapies. The hypothetical scenario in which all eligible Italian patients are treated with rosiglitazone is estimated to induce net savings for about 260 millions Euro per year. CONCLUSION: In type 2 diabetes, the maintenance of non-diabetic glycaemic levels has been shown to decrease the onset of long term complications.
DIABETES-Cost
Rosiglitazone represents a further option to postpone insulin therapy start with a potential cost-saving for the Italian National Heath System. (ADA, 2006) and interaction gender-control of DM. The ratio cost-effectiveness and incremental cost of control compared with non-control of DM was analized with WinBugs controlled for age and gender. RESULTS: Sixty-seven percent of females; average age: 69 years. The average of prescribed drugs for DM control was 1.4 drugs/per patient (1.03% acarbose; 32.99% sulphonylurea; 64.43% biguanide, 13.40% metiglinide and the 27.32% insuline). The mean of primary care visits was 14.8/per patient/year. The Diabetes control was 68% (HbA1c% < 7) with 1.34 drugs per year in controlled patients versus 1.61 drugs in non-controlled (p < 0.01). The direct health care cost of diabetic patient was €628/year (CI95%: €576-680). In patients non haemoglobin glycosilated controlled the cost was incremented in €193 per patient and the effectiveness decal in 32%. CONCLUSION: This economic study demonstrates the real possibility to improve the efficiency of our interventions. If we transferred the data found to our area of reference (Málaga) the saving in costs would be superior to €3 million. Health providers and policymakers should use this information in making clinical and policy decisions in order to use resources efficiently. 
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